Abstracts tagged "interstitial lung disease"

Abstract Number: 1569 • 2015 ACR/ARHP Annual Meeting
Rituximab Efficacy in the Treatment of Diffuse Interstitial Lung Disease Associated with Rheumatoid Arthritis
Javier Narváez¹, Milagros Ricse², Juan José Alegre³, Gloria Albert Espi³, Carmen Gomez Vaquero⁴, Helena Borrell Paños², Eulalia Armengol², Joan Miquel Nolla², Susana Herrera⁵ and Maria Molina⁶, ¹Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ²Department of Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ³Rheumatology Department, Hospital Universitario Doctor Peset, Valencia, Spain, ⁴Department of Rheumatology, Hospital Universitario Bellvitge, Barcelona, Spain, ⁵Deparment of Pneumology, Hospital Universitario Dr Peset, Valencia, Spain, ⁶Department of Pneumology, Hospital Universitario de Bellvitge, Barcelona, Spain
Background/Purpose: To investigate the efficacy and safety of rituximab (RTX) in the the management of progressive rheumatoid arthritis related interstitial lung disease (RA-ILD). Methods: An…
Abstract Number: 1583 • 2015 ACR/ARHP Annual Meeting
Identifying Risk Factors for Progression of Rheumatoid Arthritis-Associated Interstitial Lung Disease
Yashaar Chaichian¹, Dina Bassiri², Imre Noth³, Mary Strek³, Tammy Utset¹ and Rekha Vij³, ¹Medicine, Section of Rheumatology, University of Chicago Medical Center, Chicago, IL, ²Statistical & Applied Research, ACT, Inc., Iowa City, IA, ³Medicine, Section of Pulmonary/Critical Care, University of Chicago Medical Center, Chicago, IL
Background/Purpose: Interstitial lung disease (ILD) is recognized as a frequent extra-articular manifestation of rheumatoid arthritis (RA) associated with significant morbidity and mortality. Nevertheless, risk factors…
Abstract Number: 1698 • 2014 ACR/ARHP Annual Meeting
Peripheral Blood Eosinophil Counts Increase in Patients with Systemic Sclerosis and Associated with Its Disease Severity
Tamao Nakashita¹, Shinji Motojima², Katsutoshi Ando³ and Akira Dibatake⁴, ¹Department of Rheumatology and Allergy, Kameda Medical Center, Kamogawa City, Japan, ²[email protected], Kameda Medical Center, Kamogawa City, Japan, ³Depertment of Respiratoly Medicine, Juntendo university, tokyo, Japan, ⁴Rheumatology and Allergy, Kameda Medical Center, Kamogawa city, Japan
Background/Purpose : Increased levels of serum pro-fibrotic cytokines such as IL-4 and IL-13 and plasma CXCL4 have been previously reported in patients with systemic sclerosis…
Abstract Number: 1682 • 2014 ACR/ARHP Annual Meeting
Mycophenolate Mofetil Versus Azathioprine in Scleroderma-Associated Interstitial Lung Disease: Results from the Australian Scleroderma Cohort Study
Claire Owen¹, Gene Ngian², Kathleen Elford², Owen Moore³, Mandy Nikpour³, Wendy Stevens³, Susanna Proudman⁴, Janet Roddy⁵, Jane Zochling⁶, Catherine Hill⁷, Peter Nash⁸, Allan Sturgess⁹ and Joanne Sahhar², ¹Rheumatology, Monash Health, Melbourne, Australia, ²Monash Health, Melbourne, Australia, ³St Vincent's Hospital, Melbourne, Australia, ⁴Royal Adelaide Hospital, Adelaide, Australia, ⁵Royal Perth Hospital, Perth, Australia, ⁶Department of Rheumatology, Menzies Research Institute Tasmania, Hobart, TAS, Australia, ⁷Queen Elizabeth Hospital, Adelaide, Australia, ⁸Sunshine Coast Rheumatology, Maroochydore, Australia, ⁹The St George Hospital, Sydney, Australia
Background/Purpose: Systemic sclerosis-associated interstitial lung disease (SSc-ILD) is common and when progressive, associated with significant morbidity and mortality. Cyclophosphamide is frequently used as first line…
Abstract Number: 1433 • 2014 ACR/ARHP Annual Meeting
Clinical Characterization of Subclinical Rheumatoid Arthritis-Associated Interstitial Lung Disease
Masaomi Yamasaki, Rheumatology, Shin-Yokohama Yamasaki Clinic, Yokohama, Japan
Background/Purpose Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is a common manifestation of rheumatoid lung disease. Subclinical RA-ILD is most commonly identified on HRCT imaging. In…
Abstract Number: 1419 • 2014 ACR/ARHP Annual Meeting
Rituximab Use in Patients with Rheumatoid Arthritis-Associated Interstitial Lung Disease and Other Connective Tissue Disease-Associated Interstitial Lung Disease: A Single Center Experience
Sandra Chartrand^1,2, Jeffery J. Swigris³, Lina Peykova² and Aryeh Fischer⁴, ¹Rheumatology, Hôpital Maisonneuve-Rosemont, Montreal, QC, Canada, ²Rheumatology, National Jewish Health, Denver, CO, ³Autoimmune Lung Center, National Jewish Health, Denver, CO, ⁴Rheumatology / ILD Program, National Jewish Health, Denver, CO
Background/Purpose: Small series have suggested that rituximab (RTX) may be effective as rescue-therapy for connective tissue disease-associated interstitial lung disease (CTD-ILD). We sought to describe…
Abstract Number: 1273 • 2014 ACR/ARHP Annual Meeting
Assessment of the Effect of Rituximab in the Treatment of Interstitial Lung Disease associated with the Antisynthetase Syndrome
Tracy Doyle¹, Juan Osorio², Eduarda Nilo DeMagaldi³, Rachna Madan⁴, Fernanda Cabral⁵, Ivan Rosas² and Paul Dellaripa⁶, ¹Division of pulmonary medicine, Brigham and Women's Hospital, Boston, MA, ²Division of pulmonary medicine, Brigham and Women's Hospital, Boston, MA, ³medicine, Harvard Medical School, Boston, MA, ⁴Radiology, Brigham and women's Hospital, Boston, MA, ⁵Radiiology, Brigham and women's Hospital, boston, MA, ⁶Division of Rheumatology, Brigham and Women's Hospital, Boston, MA
Background/purpose: To assess clinical outcomes including pulmonary function and radiographic imaging in patients with ILD and the antisynthetase syndrome who were treated with Rituxan (RTX)Methods:…
Abstract Number: 1272 • 2014 ACR/ARHP Annual Meeting
Myositis-Specific and Myositis Associated Autoantibodies in Indian Patients with Inflammatory Myositis
Puja Srivastava, Ramnath Misra, Able Lawrence, Amita Aggarwal and Vikas Agarwal, Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India
Background/Purpose Recently, idiopathic inflammatory myositis (IIM) has been categorised into distinct subsets based on myositis specific autoantibodies (MSA) and myositis associated autoantibodies (MAA). However, there is…
Abstract Number: 432 • 2014 ACR/ARHP Annual Meeting
Rheumatoid Arthritis-Associated Interstitial Lung Disease: Risk Factors for Disease Progression
Yashaar Chaichian¹, Imre Noth¹, Mary Strek¹, Tammy O. Utset² and Rekha Vij¹, ¹University of Chicago Medical Center, Chicago, IL, ²University of Chicago, Chicago, IL
Background/Purpose Rheumatoid arthritis (RA) is the most common systemic connective tissue disease in the U.S. Interstitial lung disease (ILD) is a frequent extra-articular manifestation of…
Abstract Number: 2998 • 2014 ACR/ARHP Annual Meeting
Screening for Interstitial Lung Disease in Systemic Sclerosis: Performance of High-Resolution Computed Tomography with Limited Number of Slices – a Prospective Study
Thomas Frauenfelder¹, Anna Winklehner¹, Thi Dan Linh Nguyen¹, Rucsandra Dobrota^2,3, Stephan Baumüller¹, Britta Maurer² and Oliver Distler², ¹Institute of Diagnostic and Interventional Radiology, University Hospital Zurich, Zurich, Switzerland, ²Division of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ³Department of Internal Medicine and Rheumatology, Dr.I.Cantacuzino Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
Background/Purpose Early diagnosis of interstitial lung disease (ILD), currently the main cause of death in systemic sclerosis (SSc), is needed. The gold standard is high…
Abstract Number: 2976 • 2014 ACR/ARHP Annual Meeting
Lung Ultrasound Screening for Interstitial Lung Disease in Rheumatoid Arthritis. Comparison with Usual Detection Algorithms in Clinical Practice
Marco Antivalle, Michel Chevallard, Michele Battellino, MariaChiara Ditto, Valentina Varisco, Federica Rigamonti, Alessandra Mutti, Fabiola Atzeni, Alberto Batticciotto and Piercarlo Sarzi-Puttini, Rheumatology, L. Sacco University Hospital, Milano, Italy
Background/Purpose: interstitial lung disease (RA-ILD) is one of the most serious extraarticular complications of rheumatoid arthritis (RA). Presently, it is not clear which is the…
Abstract Number: 2697 • 2014 ACR/ARHP Annual Meeting
Gender Disparities in Lung Transplantation in Patients with Systemic Sclerosis-Related Interstitial Lung Disease and Pulmonary Hypertension
Elizabeth Volkmann¹, Daniel E. Furst², Rajeev Saggar³, Philip J. Clements⁴, Bryant Torres⁵, Lynne Yoder¹ and Rajan Saggar¹, ¹Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ²University of California, Los Angeles, CA, ³Cardiothoracic Surgery, University of Arizona College of Medicine, Phoenix, AZ, ⁴University of California, Los Angeles, Department of Medicine, Los Angeles, CA, ⁵Health Policy and Management, Rollins School of Public Health, Emory University, Atlanta, GA
Background/Purpose: Lung transplantation is often the most viable option for patients with severe systemic sclerosis (SSc)-associated interstitial lung disease (ILD) that is unresponsive to pharmacologic…
Abstract Number: 2190 • 2014 ACR/ARHP Annual Meeting
Features of Interstitial Lung Disease Associated with Connective Tissue Disease in a Spanish Southwest Cohort
Adela Gallego Flores¹, Carmen Carrasco Cubero², Raul Veroz Gonzalez¹, Luz Maria Mellado Narciso¹, Tamara Libertad Rodriguez Araya¹, Juan Jose Aznar Sánchez¹ and Eugenio Chamizo Carmona¹, ¹Rheumatology, Hospital de Mérida, Mérida, Spain, ²Rheumatology, Hospital de Merida, Mérida, Spain
Background/Purpose Diffuse interstitial lung disease (ILD) can be associated with connective tissue diseases (CTD), and can increase morbidity and mortality significantly. The predominant patterns of…
Abstract Number: 1797 • 2014 ACR/ARHP Annual Meeting
One-Year Survival of Adults with Systemic Sclerosis Following Lung Transplantation: A Nationwide Cohort Study
Elana J. Bernstein¹, Eric R. Peterson², Joan M. Bathon² and David J. Lederer², ¹Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY, ²Medicine, Columbia University College of Physicians & Surgeons, New York, NY
Background/Purpose: Lung transplantation is a potentially life-saving treatment for patients with systemic sclerosis (SSc) who have developed end-stage lung disease due to interstitial lung disease…
Abstract Number: 1784 • 2014 ACR/ARHP Annual Meeting
Prognostic Factors for Interstitial Lung Disease with Microscopic Polyangiitis
Takeshi Shoda, Tohru Takeuchi, Takaaki Ishida, Hideyuki Shiba, Youhei Fujiki, Daisuke Wakura, Shuzo Yoshida, Takuya Kotani, Shigeki Makino and Toshiaki Hanafusa, Department of Internal Medicine (I), Osaka medical college, Osaka, Japan
Background/Purpose Many patients with interstitial lung disease (ILD) complicated by microscopic polyangiitis (MPA) show a UIP pattern on chest CT. The prognosis is poorer than…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].